Purine nucleoside analogs in the therapy of cancer and neuroinflammation
2015
Autori:
Savić, DanijelaStanković, Tijana
Lavrnja, Irena
Podolski-Renić, Ana
Banković, Jasna
Peković, Sanja
Stojiljković, Mirjana
Rakić, Ljubisav
Ruždijić, Sabera
Pešić, Milica
Tip dokumenta:
Prikaz (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
Purine nucleoside analogs have been in clinical use for almost 50 years. At the beginning developed as antiviral agents, later their efficacy was demonstrated in cancer treatment, especially hematological malignances. The approval of new purine nucleoside analogs by US Food and Drug Administration (FDA) over the past decade implies that the interest for these drugs still exists. Here, we review new nucleoside analogs that are currently in preclinical or clinical development as anticancer agents. In addition, we highlight the potential for implementation of these drugs in other pathological conditions, particularly in neuroinflammation.
Ključne reči:
Purine nucleoside analogs; Cancer; Neuroinflammation; Brain injuryIzvor:
Molecular inhibitors in targeted therapy, 2015, 1, 1, 3-14Finansiranje / projekti:
- Ćelijska i molekulska osnova neuroinflamacije: potencijala ciljna mesta za translacionu medicinu i terapiju (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41014)
- Identifikacija molekularnih markera za predikciju progresije tumora, odgovora na terapiju i ishoda bolesti (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41031)
URI
http://www.degruyter.com/view/j/motth.2015.1.issue-1/motth-2015-0002/motth-2015-0002.xmlhttps://radar.ibiss.bg.ac.rs/handle/123456789/2633